REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al; Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level results from the global burden of disease study 2015. JAMA Oncol 2017;3:1683-91.
3. Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res 2019;49:1109-13.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
5. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
6. Bralet MP, Régimbeau JM, Pineau P, Dubois S, Loas G, et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000;32:200-4.
8. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-40.
9. Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl 2006;12:966-71.
10. Miyagawa S, Makuuchi M, Kawasaki S, Kakazu T. Criteria for safe hepatic resection. Am J Surg 1995;169:589-94.
11. Seyama Y, Kokudo N. Assessment of liver function for safe hepatic resection. Hepatol Res 2009;39:107-16.
12. Serenari M, Collaud C, Alvarez FA, de Santibañes M, Giunta D, et al. Interstage assessment of remnant liver function in alpps using hepatobiliary scintigraphy: prediction of posthepatectomy liver failure and introduction of the HIBA index. Ann Surg 2018;267:1141-7.
13. Serenari M, Pettinato C, Bonatti C, Zanoni L, Odaldi F, et al. Hepatobiliary scintigraphy in the preoperative evaluation of potential living liver donors. Transplant Proc 2019;51:167-70.
14. Cucchetti A, Cescon M, Golfieri R, Piscaglia F, Renzulli M, et al. Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. J Hepatol 2016;64:79-86.
15. Qi X, Zhang X, Li Z, Hui J, Xiang Y, et al. HVPG signature: A prognostic and predictive tool in hepatocellular carcinoma. Oncotarget 2016;7:62789-96.
16. Cescon M, Colecchia A, Cucchetti A, Peri E, Montrone L, et al. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg 2012;256:706-12.
17. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, et al. Reply to Letter: “A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational Study of the HCC East-West Study Group”: when the study setting “ignores” the patients. Ann Surg 2015;262:e30-1.
18. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-7.
19. Meniconi RL, Komatsu S, Perdigao F, Boëlle PY, Soubrane O, et al. Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery 2015;157:454-62.
20. Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 2003;237:536-43.
21. Xing H, Zhang WG, Cescon M, Liang L, Li C, et al. Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. HPB (Oxford) 2019; doi: 10.1016/j.hpb.2019.09.006.
22. Joliat GR, Allemann P, Labgaa I, Demartines N, Halkic N. Treatment and outcomes of recurrent hepatocellular carcinomas. Langenbecks Arch Surg 2017;402:737-44.
23. Erridge S, Pucher PH, Markar SR, Malietzis G, Athanasiou T, et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. Br J Surg 2017;104:1433-42.
24. Wu CC, Cheng SB, Yeh DC, Wang J, P’eng FK. Second and third hepatectomies for recurrent hepatocellular carcinoma are justified. Br J Surg 2009;96:1049-57.
25. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-7.
26. Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 2015;261:947-55.
27. Nagasue N, Yukaya H, Ogawa Y, Sasaki Y, Chang YC, et al. Second hepatic resection for recurrent hepatocellular carcinoma. Br J Surg 1986;73:434-8.
28. Hu RH, Lee PH, Yu SC, Dai HC, Sheu JC, et al. Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. Surgery 1996;120:23-9.
29. Lee PH, Lin WJ, Tsang YM, Hu RH, Sheu JC, et al. Clinical management of recurrent hepatocellular carcinoma. Ann Surg 1995;222:670-6.
30. Shimada M, Takenaka K, Taguchi K, Fujiwara Y, Gion T, et al. Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg 1998;227:80-5.
31. Sun HC, Tang ZY, Ma ZC, Qin LX, Wang L, et al. The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background. J Cancer Res Clin Oncol 2005;131:284-8.
32. Huang ZY, Liang BY, Xiong M, Zhan DQ, Wei S, et al. Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China. Ann Surg Oncol 2012;19:2515-25.
33. Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 2003;238:703-10.
34. Roayaie S, Bassi D, Tarchi P, Labow D, Schwartz M. Second hepatic resection for recurrent hepatocellular cancer: a Western experience. J Hepatol 2011;55:346-50.
35. Zou Q, Li J, Wu D, Yan Z, Wan X, et al. Nomograms for pre-operative and post-operative prediction of long-term survival of patients who underwent repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg Oncol 2016;23:2618-26.
36. Chan DL, Morris DL, Chua TC. Clinical efficacy and predictors of outcomes of repeat hepatectomy for recurrent hepatocellular carcinoma - a systematic review. Surg Oncol 2013;22:e23-30.
37. Huang ZY, Liang BY, Xiong M, Zhan DQ, Wei S, et al. Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China. Ann Surg Oncol 2012;19:2515-25.
38. Faber W, Seehofer D, Neuhaus P, Stockmann M, Denecke T, et al. Repeated liver resection for recurrent hepatocellular carcinoma. J Gastroenterol Hepatol 2011;26:1189-94.
39. Kubo S, Takemura S, Uenishi T, Yamamoto T, Ohba K, et al. Second hepatic resection for recurrent hepatocellular carcinoma in patients with chronic hepatitis C. World J Surg 2008;32:632-8.
40. Itamoto T, Nakahara H, Amano H, Kohashi T, Ohdan H, et al. Repeat hepatectomy for recurrent hepatocellular carcinoma. Surgery 2007;141:589-97.
41. Tralhão JG, Dagher I, Lino T, Roudié J, Franco D. Treatment of tumour recurrence after resection of hepatocellular carcinoma. Analysis of 97 consecutive patients. Eur J Surg Oncol 2007;33:746-51.
42. Kobayashi A, Kawasaki S, Miyagawa S, Miwa S, Noike T, et al. Results of 404 hepatic resections including 80 repeat hepatectomies for hepatocellular carcinoma. Hepatogastroenterology 2006;53:736-41.
43. Sugimachi K, Maehara S, Tanaka S, Shimada M, Sugimachi K. Repeat hepatectomy is the most useful treatment for recurrent hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2001;8:410-6.
44. Hu RH, Lee PH, Yu SC, Dai HC, Sheu JC, et al. Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. Surgery 1996;120:23-9.
45. Cai W, Liu Z, Xiao Y, Zhang W, Tang D, et al. Comparison of clinical outcomes of laparoscopic versus open surgery for recurrent hepatocellular carcinoma: a meta-analysis. Surg Endosc 2019;33:3550-7.
46. Halls MC, Berardi G, Cipriani F, Barkhatov L, Lainas P, et al. Development and validation of a difficulty score to predict intraoperative complications during laparoscopic liver resection. Br J Surg 2018;105:1182-91.
47. Majno PE, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology 2000;31:899-906.
48. Kostakis ID, Machairas N, Prodromidou A, Stamopoulos P, Garoufalia Z, et al. Comparison between salvage liver transplantation and repeat liver resection for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Transplant Proc 2019;51:433-6.
49. Lim C, Shinkawa H, Hasegawa K, Bhangui P, Salloum C, et al. Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: An intent-to-treat analysis. Liver Transpl 2017;23:1553-63.
50. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 2003;238:508-18.
51. Wang HL, Mo DC, Zhong JH, Ma L, Wu FX, et al. Systematic review of treatment strategy for recurrent hepatocellular carcinoma: Salvage liver transplantation or curative locoregional therapy. Medicine (Baltimore) 2019;98:e14498.
52. Lucidi V, Gustot T, Moreno C, Donckier V. Liver transplantation in the context of organ shortage: toward extension and restriction of indications considering recent clinical data and ethical framework. Curr Opin Crit Care 2015;21:163-70.
53. Taura K, Ikai I, Hatano E, Fujii H, Uyama N, et al. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg 2006;244:265-73.
54. Lü MD, Kuang M, Liang LJ, Xie XY, Peng BG, et al. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. Zhonghua Yi Xue Za Zhi 2006;86:801-5. (in Chinese)
55. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-8.
56. Chan AC, Poon RT, Cheung TT, Chok KS, Chan SC, et al. Survival analysis of re-resection versus radiofrequency ablation for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. World J Surg 2012;36:151-6.
57. Gavriilidis P, Askari A, Azoulay D. Survival following redo hepatectomy vs radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford) 2017;19:3-9.
58. Thomasset SC, Dennison AR, Garcea G. Ablation for recurrent hepatocellular carcinoma: a systematic review of clinical efficacy and prognostic factors. World J Surg 2015;39:1150-60.
59. Wang K, Liu G, Li J, Yan Z, Xia Y, et al. Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: a prospective cohort study. Eur J Surg Oncol 2015;41:236-42.
60. Malagari K, Alexopoulou E, Chatzimichail K, Hall B, Koskinas J, et al. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging 2008;33:512-9.
61. Llovet JM, Real MI, Montaña X, Planas R, Coll S, et al; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
62. Jin YJ, Lee JW, Lee OH, Chung HJ, Kim YS, et al. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion. J Gastroenterol Hepatol 2014;29:1056-64.
63. Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, et al; Liver Cancer Study Group of Japan. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol 2010;194:830-7.
64. Erridge S, Pucher PH, Markar SR, Malietzis G, Athanasiou T, et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. Br J Surg 2017;104:1433-42.
65. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
66. Bruix J, Qin S, Merle P, Granito A, Huang YH, et al; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
67. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.